Eisai

Profilo dell'azienda

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Descrizione disponibile in inglese.

Dati societari

Settore

Salute

Industria

Drug Manufacturers - Specialty & Generic

Paese

Giappone

Sede

4-6-10 Koishikawa, 112-8088, Tokyo

Dipendenti

10.543

Quotazione

4523 · TSE

Indici

Nikkei 225

Valuta

JPY

ISIN

JP3160400002

Sito web

eisai.co.jp